Contents

Highlights of This Issue 1

SPECIAL FEATURES

CCR Translations

3 The Importance of Doing Trials Right While Doing the Right Trials
   David M. Dilts and Steven K. Cheng
   See article p. 256

6 Elusive Extraneural Estrogen Receptors in Breast Cancer
   Ellis R. Levin
   See article p. 118

CCR Drug Updates

9 Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma
   Jason J. Luke and F. Stephen Hodi

Molecular Pathways

15 Molecular Pathways: Targeting Proteasomal Protein Degradation in Cancer
   Susan M. Molineaux

CCR Focus

22 On Drug Development, Chance, and the Prepared Mind
   Susan E. Bates

23 Drug Development: Portals of Discovery
   Susan E. Bates, Laleh Amiri-Kordestani, and Giuseppe Giaconne

33 BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance
   Alexander Marzuka Alcalá and Keith T. Flaherty

40 The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology
   Michael Pollak

51 Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale
   Edina Komlodi-Pasztor, Dan L. Sackett, and Antonio Tito Fojo

HUMAN CANCER BIOLOGY

64 Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
   Len Neckers and Paul Workman

77 Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy

91 Eph-B2/Ephrin-B2 Interaction Plays a Major Role in the Adhesion and Proliferation of Waldenstrom's Macrogloblinemia
   Feda Azab, Abdel Karem Azab, Patricia Maise, Teresa Calimeri, Ludmila Flores, Yang Liu, Phong Quang, Aldo M. Roccaro, Antonio Sacco, Hai T. Ngo, Yong Zhang, Britanny L. Morgan, Ruben D. Carrasco, and Irene M. Ghobrial

105 Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness
   Dieter Lemke, Philipp-Niclas Pfenninger, Felix Sahn, Ann-Catherine Klein, Tore Kempf, Uwe Warnken, Martina Schnölder, Ruxandra Tudoran, Michael Weller, Michael Platten, and Wolfgang Wick

118 Cytoplasmic Estrogen Receptor in Breast Cancer
   Allison W. Welsh, Donald R. Lannin, Gregory S. Young, Mark E. Sherman, Jonine D. Figueroa, N. Lynn Henry, Lisa Ryden, Chungyeul Kim, Richard R. Love, Rachel Schiff, and David L. Rimm
   See commentary p. 6

CANCER THERAPY: PRECLINICAL

127 STAT5A-Mediated SOCS2 Expression Regulates Jak2 and STAT3 Activity Following e-Src Inhibition in Head and Neck Squamous Carcinoma
Phenylarsine Oxide Induces Apoptosis in Bax- and Bak-Deficient Cells through Upregulation of Bim
Biyun Ni, Qi Ma, Baowei Li, Lixia Zhao, Yong Liu, Yushan Zhu, and Quan Chen

Synergistic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 with Chemotherapy
Rajat Singh, Yujian Zhang, Ira Pastan, and Robert J. Kreitman

Modulation of the Tumor Microvasculature by Phosphoinositide-3 Kinase Inhibition Increases Doxorubicin Delivery In Vivo
Naseer Qayum, Jaehong Im, Michael R. Stratford, Eric J. Bernhard, W. Gillies McKenna, and Ruth J. Muschel

Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells
Dimpy Koul, Jun Fu, Ruijun Shen, Tiffany A. LaFortune, Shuzhen Wang, Ningyi Tiao, Yong-Wan Kim, Juinn-Lin Liu, Deepti Ramnarian, Ying Yuan, Carlos Garcia-Echevarria, Sauveur-Michel Maira, and W.K. Alfred Yung

Validation of Genetic Sequence Variants as Prognostic Factors in Early-Stage Head and Neck Squamous Cell Cancer Survival
Abul Kalam Azad, Isabelle Bairati, Eloide Samson, Dangxiao Cheng, Maryam Mirshams, Xi Qu, Sevtap Savas, John Waldron, Changhui Wang, David Goldstein, Wei Xu, Francois Meyer, and Geoffrey Liu

Noninvasive Detection of Breast Cancer Lymph Node Metastasis Using Carbonic Anhydrases IX and XII Targeted Imaging Probes
Narges K. Tafreshi, Marilyn M. Bui, Kelsey Bishop, Mark C. Lloyd, Steven A. Ecekemann, Alexis S. Lopez, Dominique Abrahams, Bradford W. Carter, Josef Vagner, Stephen R. Grobmyer, Robert J. Gillies, and David L. Morse

Early [18F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung
Ryo Takahashi, Haruhiko Hirata, Isao Tachibana, Eku Shimosegawa, Atsuo Inoue, Izumi Nagatomo, Yoshito Takeda, Hiroshi Kida, Sho Goya, Takashi Kijima, Mitsuhiro Yoshida, Toru Kumagai, Atsushi Kumanogoh, Meisoshin Okumura, Jun Hatazawa, and Ichiro Kawase

Lymphatic Invasion Is Independently Prognostic of Metastasis in Primary Cutaneous Melanoma
Xiaowei Xu, Lianjun Chen, DuPont Guerry, Peter R. Dawson, Wei-ting Hwang, Patricia Vanielle, David E. Elder, Paul J. Zhang, Michael E. Ming, Lynn Schuchter, and Phyllis A. Gimotty

In Vivo Positron Emission Tomography Imaging of Protease Activity by Generation of a Hydrophobic Product from a Noninhibitory Protease Substrate

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
Michelle A. Fanale, Andres Forero-Torres, Joseph D. Rosenblatt, Ranjan A. Advani, Anna R. Franklin, Dana A. Kennedy, Tae H. Han, Eric L. Sievers, and Nancy L. Bartlett

Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups

See commentary p. 3
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>263</td>
<td>Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1</td>
<td>Jean Philippe Arnault, Christine Mateus, Bernard Escudier, Gorana Tomasic, Janine Wechsler, Emilie Hollville, Jean-Charles Soria, David Malka, Alain Sarasin, Magalie Larcher, Jocelyne André, Nyam Kamsu-Kom, Lise Boussenart, Ludovic Lacroix, Alain Spatz, Alexander M. Eggermont, Sabine Druiillenc, Stephan Vagner, Alain Eychène, Nicolas Dumaz, and Caroline Robert</td>
</tr>
<tr>
<td>273</td>
<td>Concurrent Temozolomide and Dose-Escalated Intensity-Modulated Radiation Therapy in Newly Diagnosed Glioblastoma</td>
<td>Christina I. Tsien, Doris Brown, Daniel Normolle, Matthew Schipper, Morand Piert, Larry Junck, Jason Heth, Diana Gomez-Hassan, Randall K. Ten Haken, Thomas Chenevert, Yue Cao, and Theodore Lawrence</td>
</tr>
</tbody>
</table>

**PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>280</td>
<td>Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer</td>
<td>Sonal Gupta, Dipankar Pramanik, Radha Mukherjee, Nathaniel R. Campbell, Sathyanarayanan Elumalai, Roeland F. de Wilde, Seung-Mo Hong, Michael G. Goggins, Ana De Jesus-Acosta, Daniel Lafer, and Anirban Maitra</td>
</tr>
<tr>
<td>290</td>
<td>TP53 Disruptive Mutations Lead to Head and Neck Cancer Treatment Failure through Inhibition of Radiation-Induced Senescence</td>
<td>Heath D. Skinner, Vlad C. Sandulache, Thomas J. Ow, Raymond E. Meyn, John S. Yordy, Beth M. Beadle, Alison L. Fitzgerald, Uma Giri, K. Kian Ang, and Jeffrey N. Myers</td>
</tr>
</tbody>
</table>

**LETTER TO THE EDITOR**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>301</td>
<td>Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial</td>
<td>Annette M. Lim, Danny Rischin, Richard Fisher, Hongbin Cao, Kathleen Kwok, Daniel Truong, Grant A. McArthur, Richard J. Young, Amato Giaccia, Lester Peters, and Quynh-Thi Le</td>
</tr>
</tbody>
</table>

**CORRECTIONS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>308</td>
<td>VKX3.1 Haploinsufficiency Is Prognostic for Prostate Cancer Relapse following Surgery or Image-Guided Radiotherapy</td>
<td>Jennifer A. Locke, Gaetano Zafarana, Adrian S. Ishkanian, Michael Milosevic, John Thoms, Cherry L. Have, Chad A. Mallof, Wan L. Lam, Jeremy A. Squire, Melanie Pintilie, Jenna Sykes, Varune Rohan Rammarine, Alice Meng, Omer Ahmed, Igor Jurisica, Theo van der Kwast, and Robert G. Bristow</td>
</tr>
<tr>
<td>317</td>
<td>A CDD Polymorphism as Predictor of Capecitabine-Induced Hand-Foot Syndrome—Letter</td>
<td>Joseph Ciccolini, Alexandre Evrard, and Bruno Lacarelle</td>
</tr>
<tr>
<td>318</td>
<td>Correction: Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance</td>
<td></td>
</tr>
<tr>
<td>319</td>
<td>Correction: ABCB1 (MDR1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy</td>
<td></td>
</tr>
</tbody>
</table>
ABOUT THE COVER

B7H3 represents a novel driver of gliomagenesis by mediating an immunosuppressive and proinvasive phenotype in glioblastoma. Immunofluorescence demonstrates the perivascularly (alpha-SMA staining; red) enhanced expression of B7H3 (vesicular distribution; green) in human glioblastoma tissue (nuclei staining; blue). For details, see the article by Lemke and colleagues on page 105 of this issue.